北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 血液科  > 期刊论文
学科主题: 临床医学
题名:
Bortezomib improves progression-free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma
作者: Qin Yazhen1; Lu Jin1; Bao Li1; Zhu Honghu1; Li Jinlan1; Li Lingdi1; Lai Yueyun1; Shi Hongxia1; Wang Yazhe1; Liu Yanrong1; Jiang Bin1; Huang Xiaojun1,2
关键词: multiple myeloma ; preferentially expressed antigen of melanoma expression ; bortezomib ; progression-free survival ; real-time quantitative polymerase chain reaction
刊名: CHINESE MEDICAL JOURNAL
发表日期: 2014-05-05
DOI: 10.3760/cma.j.issn.0366-6999.20132356
卷: 127, 期:9, 页:1666-1671
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Medicine, General & Internal
研究领域[WOS]: General & Internal Medicine
关键词[WOS]: STEM-CELL TRANSPLANTATION ; MINIMAL RESIDUAL DISEASE ; REFRACTORY MYELOMA ; PROGNOSTIC-FACTORS ; LEUKEMIA PATIENTS ; PRAME EXPRESSION ; STAGING SYSTEM ; MANAGEMENT ; PATTERNS ; THERAPY
英文摘要:

Background Significant efforts have been made to identify factors that differentiate patients treated with novel therapies, such as bortezomib in multiple myeloma (MM). The exact expression pattern and prognostic value of the cancer/testis antigen preferentially expressed antigen of melanoma (PRAME) in MM are unknown and were explored in this study.

Methods The transcript level of FRAME was detected in bone marrow specimens from 100 newly diagnosed MM patients using real-time quantitative polymerase chain reaction, and the prognostic value of FRAME was determined through retrospective survival analysis. FRAME expression higher than the upper limit of normal bone marrow was defined as PRAME overexpression or FRAME (+).

Results Sixty-two patients (62.0%) overexpressed FRAME. FRAME overexpression showed no prognostic significance to either overall survival (n=100) or progression-free survival (PFS, n=96, all P > 0.05) of patients. The patients were also categorized according to regimens with or without bortezomib. FRAME overexpression tended to be associated with a lower two-year PFS rate in patients treated with non-bortezomib-containing regimens (53.5% vs. 76.9%, P=0.071). By contrast, it was not associated with the two-year PFS rate in patients with bortezomib-containing regimens (77.5% vs. 63.9%, P > 0.05). When the patients were categorized into PRAME (+) and FRAME () groups, treatment with bortezomib-containing regimens predicted a higher two-year PFS rate in FRAME (+) patients (77.5% vs. 53.5%, P=0.027) but showed no significant effect on two-year PFS rate in FRAME () patients (63.9% vs. 76.9%, P > 0.05).

Conclusion FRAME overexpression might be an adverse prognostic factor of PFS in MM patients treated with non-bortezonnib-containing regimens. Bortezomib improves PFS in patients overexpressing PRAME.

语种: 英语
所属项目编号: Z111107067311070 ; 81170483 ; 81372535
项目资助者: Beijing Municipal Science and Technology Program ; Nature Science Foundation of China
WOS记录号: WOS:000335936800012
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/68197
Appears in Collections:北京大学第二临床医学院_血液科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Peoples Hosp, Inst Hematol, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing 100044, Peoples R China
2.Peking Univ, Peking Tsinghua Ctr Life Sci, Beijing 100871, Peoples R China

Recommended Citation:
Qin Yazhen,Lu Jin,Bao Li,et al. Bortezomib improves progression-free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma[J]. CHINESE MEDICAL JOURNAL,2014,127(9):1666-1671.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Qin Yazhen]'s Articles
[Lu Jin]'s Articles
[Bao Li]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Qin Yazhen]‘s Articles
[Lu Jin]‘s Articles
[Bao Li]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace